...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Repeat stereotactic radiosurgery for acoustic neuromas.
【24h】

Repeat stereotactic radiosurgery for acoustic neuromas.

机译:重复立体定向放射外科治疗听神经瘤。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the outcome of repeat stereotactic radiosurgery (SRS) for acoustic neuromas, we assessed tumor control, clinical outcomes, and the risk of adverse radiation effects in patients whose tumors progressed after initial management. METHODS AND MATERIALS: During a 21-year experience at our center, 1,352 patients underwent SRS as management for their acoustic neuromas. We retrospectively identified 6 patients who underwent SRS twice for the same tumor. The median patient age was 47 years (range, 35-71 years). All patients had imaging evidence of tumor progression despite initial SRS. One patient also had incomplete surgical resection after initial SRS. All patients were deaf at the time of the second SRS. The median radiosurgery target volume at the time of the initial SRS was 0.5 cc and was 2.1 cc at the time of the second SRS. The median margin dose at the time of the initial SRS was 13 Gy and was 11 Gy at the time of the second SRS. The median interval between initial SRS and repeat SRS was 63 months (range, 25-169 months). RESULTS: At a median follow-up of 29 months after the second SRS (range, 13-71 months), tumor control or regression was achieved in all 6 patients. No patient developed symptomatic adverse radiation effects or new neurological symptoms after the second SRS. CONCLUSIONS: With this limited experience, we found that repeat SRS for a persistently enlarging acoustic neuroma can be performed safely and effectively.
机译:目的:为了评估重复立体定向放射外科手术(SRS)治疗听神经瘤的结果,我们评估了肿瘤控制,临床结局以及在初次治疗后进展为肿瘤的患者中不良放射作用的风险。方法和材料:在我们中心的21年经验中,有1,352例患者接受了SRS来管理他们的听神经瘤。我们回顾性鉴定了6例因同一肿瘤两次接受SRS的患者。患者中位年龄为47岁(范围35-71岁)。尽管有最初的SRS,所有患者均具有肿瘤进展的影像学证据。初次SRS后,一名患者的手术切除也不完全。在第二次SRS时所有患者均失聪。初次SRS时的放射外科手术目标中位数为0.5 cc,第二次SRS时为2.1 cc。初次SRS时的中位边缘剂量为13 Gy,第二次SRS时为11 Gy。初始SRS和重复SRS之间的中位间隔为63个月(范围为25-169个月)。结果:在第二次SRS后29个月的中位随访(范围13-71个月)中,所有6例患者均实现了肿瘤控制或消退。在第二次SRS后,没有患者出现症状性不良放射效应或新的神经系统症状。结论:凭借有限的经验,我们发现对于持续扩大的听神经瘤,可以安全有效地进行重复SRS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号